KPV

A three-amino-acid fragment of alpha-MSH — the anti-inflammatory closer in the GLOW/KLOW stack family.

⚠ Safety first — read this before anything else on this page

Approval status: KPV is not FDA-approved for any use. In July 2026, FDA staff told the federal compounding advisory committee they found insufficient evidence to evaluate KPV for any indication. As of November 2026 it sits inside the draft enforcement-discretion policy — discretion is not approval.

What has actually happened to people:

No adverse events in humans are on record — because there is essentially no published human exposure record to draw from. An empty file here means unstudied, not safe.

What nobody knows: KPV's whole human profile is unknown: no human safety data, no interaction data, no long-term data. As an alpha-MSH fragment it belongs to the melanocortin family; family-level effects on pigmentation and appetite are conceivable but unstudied for KPV itself — do not import melanotan II's harm record onto KPV, and do not read the absence of one as reassurance either.

Get medical care now if:

Swelling of the lips or tongue, or trouble breathing, after any injection — call emergency services.
New or changing skin pigmentation, or any mole that changes — see a dermatologist and say what you have been taking.
An injection site that worsens over days, or a lump appearing one to several weeks later — the delayed infection pattern; it needs a clinician.

Who should stay away: Minors and anyone pregnant — no safety data exists at all. Anyone whose gut symptoms have never been worked up: symptoms self-managed with an anti-inflammatory peptide are symptoms not being diagnosed.

The product problem: Across more than 7,000 gray-market samples of all compounds, independent tester Finnrick Analytics reports roughly one in three fail basic expectations — wrong identity, wrong quantity, or contamination (February 2026). KPV has no compound-specific testing dataset to reassure anyone.

Talk to a doctor who knows you are taking it. See our doctors directory. If you were harmed, report it to FDA MedWatch — your report is how the record gets built.

We don't publish doses, protocols, or sources — for any compound, ever. Our Legal Mandate.

What it is

A three-amino-acid fragment of alpha-MSH — the anti-inflammatory closer in the GLOW/KLOW stack family.

What creators claim

Dr. Froese describes KPV as shutting down two major inflammatory pathways (NF-kB and MAPK), supporting gut-lining integrity, and showing antimicrobial/antifungal properties in research models — the piece that ‘keeps the dust settled’ in her KLOW framing. It also anchors creator ‘gut stack’ combinations with oral BPC-157.

What the evidence shows

Preclinical. No human trials establish efficacy; the anti-inflammatory mechanism story is coherent and unproven in people.

Forms it is discussed in

Oral/capsule and sublingual forms are prominent in creator content (including liposomal products from seller-clinicians — labeled as such in our research).

Dangers on record

Human safety data is thin; immune-modulating claims cut both ways and are unstudied long-term. See Dangers.

Legal status (as of November 7, 2026)

Not FDA-approved. PCAC voted 8–6 for the Bulks List (July 2026); not on the list. One of the six in the October 30 enforcement-discretion policy (acetate, single-ingredient, conditions).